Epigen Pharmaceuticals Overview
- Year Founded
-
2013

- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Epigen Pharmaceuticals General Information
Description
Developer of cardiac reperfusion therapies designed to prevent ischemia-reperfusion injury. The company's therapies involves the use of histone deacetylase (HDAC) inhibitors for reducing myocardial infarct size following acute myocardial infarction and restoring normal blood flow, thereby assisting physicians with an effective pharmaceutical intervention for protecting the cardiomyocyte from reperfusion injury.
Contact Information
Website
www.epigenpharma.comCorporate Office
- 3160 Chestnut Street Suite- 200
- Philadelphia, PA 19104
- United States
Corporate Office
- 3160 Chestnut Street Suite- 200
- Philadelphia, PA 19104
- United States
Epigen Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Out of Business | 17-Sep-2020 | Completed | Out of Business | |||
1. Accelerator/Incubator | 01-Jan-2014 | Completed | Startup |
Epigen Pharmaceuticals FAQs
-
When was Epigen Pharmaceuticals founded?
Epigen Pharmaceuticals was founded in 2013.
-
Where is Epigen Pharmaceuticals headquartered?
Epigen Pharmaceuticals is headquartered in Philadelphia, PA.
-
What industry is Epigen Pharmaceuticals in?
Epigen Pharmaceuticals’s primary industry is Therapeutic Devices.
-
Is Epigen Pharmaceuticals a private or public company?
Epigen Pharmaceuticals is a Private company.
-
What is Epigen Pharmaceuticals’s current revenue?
The current revenue for Epigen Pharmaceuticals is
.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »